HIV vaccines: a brief overview. (Q38210557)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813074%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

HIV vaccines: a brief overview (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813074%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813074%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

D Lema

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813074%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

A Garcia

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813074%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

1 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813074%20AND%20SRC:MED&resulttype=core&format=json

Scandinavian Journal of Immunology

17 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813074%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

80

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813074%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

1-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813074%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24813074%20AND%20SRC:MED&resulttype=core&format=json

New clinical trial designs for HIV vaccine evaluation

17 March 2020

cites work

1 reference

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide

21 January 2018

1 reference

HIV-1 vaccines and adaptive trial designs

21 January 2018

1 reference

New directions for HIV vaccine development from animal models

21 January 2018

1 reference

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

21 January 2018

1 reference

Cell-Mediated Immunity in Elite Controllers Naturally Controlling HIV Viral Load.

21 January 2018

1 reference

Cellular human immunodeficiency virus (HIV)-protective factors: a comparison of HIV-exposed seronegative female sex workers and female blood donors in Abidjan, Côte d'Ivoire

21 January 2018

1 reference

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

21 January 2018

1 reference

Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection

21 January 2018

1 reference

Expansion of HIV-specific T follicular helper cells in chronic HIV infection

21 January 2018

1 reference

Antibodies in HIV-1 vaccine development and therapy

21 January 2018

1 reference

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

21 January 2018

1 reference

Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth

21 January 2018

1 reference

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

21 January 2018

1 reference

Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization

21 January 2018

1 reference

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

21 January 2018

1 reference

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

21 January 2018

1 reference

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

21 January 2018

1 reference

Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function

21 January 2018

1 reference

Neutralizing antibodies to HIV-1 induced by immunization.

21 January 2018

1 reference

Role of humoral immunity in host defense against HIV.

21 January 2018

1 reference

The Antibody Response against HIV-1

21 January 2018

1 reference

Fc receptor-mediated antiviral antibodies

21 January 2018

1 reference

Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01_AE gp120.

21 January 2018

1 reference

Mapping the journey to an HIV vaccine

21 January 2018

1 reference

Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques

21 January 2018

1 reference

A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers

21 January 2018

1 reference

Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers

21 January 2018

1 reference

Harnessing CD4⁺ T cell responses in HIV vaccine development

21 January 2018

1 reference

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

21 January 2018

1 reference

Vaccine design for CD8 T lymphocyte responses

21 January 2018

1 reference

The antiviral efficacy of HIV-specific CD8⁺ T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate

21 January 2018

1 reference

Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance

21 January 2018

1 reference

A brief history of the global effort to develop a preventive HIV vaccine

21 January 2018

1 reference

Novel directions in HIV-1 vaccines revealed from clinical trials

21 January 2018

1 reference

Human immunodeficiency virus vaccine an update

21 January 2018

1 reference

The design and evaluation of HIV-1 vaccines

21 January 2018

1 reference

Vaccine adjuvants: mode of action

21 January 2018

1 reference

An overview of adjuvant formulations and delivery systems.

21 January 2018

1 reference

Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms

21 January 2018

1 reference

Immunologic considerations for generating memory CD8 T cells through vaccination.

21 January 2018

1 reference

Dendritic cell based vaccines for HIV infection: the way ahead

21 January 2018

1 reference

HIV reservoirs: pathogenesis and obstacles to viral eradication and cure

21 January 2018

1 reference

Establishment and molecular mechanisms of HIV-1 latency in T cells

21 January 2018

1 reference

Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys

21 January 2018

1 reference

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

21 January 2018

1 reference

A global approach to HIV-1 vaccine development

21 January 2018

1 reference

Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers

21 January 2018

1 reference

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

21 January 2018

1 reference

Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic

21 January 2018

1 reference

A formalin-inactivated whole SIV vaccine confers protection in macaques

21 January 2018

1 reference

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

21 January 2018

1 reference

Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety

21 January 2018

1 reference

Development of replication-competent viral vectors for HIV vaccine delivery

21 January 2018

1 reference

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

Human immunodeficiency virus vaccine trials

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate

21 January 2018

1 reference

Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody

21 January 2018

1 reference

Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41.

21 January 2018

1 reference

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways

21 January 2018

1 reference

Recombinant vaccines and the development of new vaccine strategies.

21 January 2018

1 reference

Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling

21 January 2018

1 reference

Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies.

21 January 2018

1 reference

Nonreplicating vectors in HIV vaccines

21 January 2018

1 reference

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

21 January 2018

1 reference

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans

21 January 2018

1 reference

Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine

21 January 2018

1 reference

Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5.

21 January 2018

1 reference

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope

21 January 2018

1 reference

Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.

21 January 2018

1 reference

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

21 January 2018

1 reference

Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review

21 January 2018

1 reference

HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality

21 January 2018

1 reference

DNA vaccines: a simple DNA sensing matter?

21 January 2018

1 reference

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery

21 January 2018

1 reference

PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice

21 January 2018

1 reference

Potent T cell responses induced by single DNA vaccine boosted with recombinant vaccinia vaccine

21 January 2018

1 reference

HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques.

21 January 2018

1 reference

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

21 January 2018

1 reference

Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen

21 January 2018

1 reference

Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens

21 January 2018

1 reference

The ABC of clinical and experimental adjuvants--a brief overview

21 January 2018

1 reference

Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).

21 January 2018

1 reference

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate

21 January 2018

1 reference

Antibodies and their receptors: different potential roles in mucosal defense.

21 January 2018

1 reference

Immunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routes

21 January 2018

1 reference

Systemic vaccination induces clonally diverse SIV-specific CD8+ T-cell populations in systemic and mucosal compartments

21 January 2018

1 reference

Unique IL-13Rα2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity.

21 January 2018

1 reference

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

21 January 2018

1 reference

New paradigms for HIV/AIDS vaccine development

21 January 2018

1 reference